FDA approved 11 new agents, 30 supplemental indications in cancer in 2019

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Last year, FDA approved 11 new drugs and biologics as well as 30 supplemental indications and four biosimilars, according to commentary by FDA officials published in Nature Reviews.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

In a new article on the Cancer History Project, the American Cancer Society profiles three ACS-funded Nobel laureates:  David Baker, PhD2024 Nobel PrizeChemistry Victor Ambrose, PhD 2024 Nobel Prize Physiology or Medicine Gary Ruvkun, PhD2024 Nobel Prize Physiology or Medicine They join a cohort of 50 other ACS-funded Nobel laureates.  “The American Cancer Society’s legacy, with 53 Nobel...

Alexandria Carolan
Alexandria Carolan
Reporter

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login